In the following year, the Food and Drug Administration (FDA) granted approval for the PD-1 specific mAbs Nivolumab (Opdivo) (37) and Pembrolizumab (Keytruda) (38) as well as for the PD-L1 targeting antibodies Avelumab (Bavencio) (37, 38) and Durvalumab (Imfinzi) (38, 39) for locally advanced or metastatic UC showing tumor progression during or after adjuvant therapy utilizing platinum-containing chemotherapy or neoadjuvant treatment. This evidence concerns the gene PDCD1 and neoplasm.